Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Schedule of Accrued Expenses and Other Current Liabilities Schedule of Accrued Liabilities [Table Text Block] Research and development Research and Development Expense Amounts invoiced as prepayments for product supply Contract With Customer, Liability, Revenue Invoiced As Prepayments For Product Supply, Current Contract With Customer, Liability, Revenue Invoiced As Prepayments For Product Supply, Current Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Award Type [Domain] Award Type [Domain] Fair Value as of Grant Date Award Grant Date Fair Value Milwaukee facility Facility, Milwaukee Wisconsin [Member] Facility, Milwaukee Wisconsin XPHOZAH Product, XPHOZAH [Member] Product, XPHOZAH Insider Trading Policies and Procedures [Line Items] Options exercisable (shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Stockholders' Equity Equity [Text Block] Options vested and expected to vest Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Elizabeth Grammer [Member] Elizabeth Grammer Dividend yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Issuance of common stock upon vesting of restricted stock units (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Board of directors Director [Member] Customer [Axis] Customer [Axis] Current liabilities: Liabilities, Current [Abstract] Federal Deferred Federal Income Tax Expense (Benefit) Preferred stock, $0.0001 par value; 5,000,000 shares authorized; no shares issued and outstanding Preferred Stock, Value, Issued Equity Incentive Plans Share-Based Payment Arrangement, Disclosure [Abstract] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Net loss per share of common stock - diluted (in dollars per share) Net loss per share - diluted (in dollars per share) Earnings Per Share, Diluted Accounts receivable Accounts Receivable, after Allowance for Credit Loss, Current Receivable [Domain] Receivable [Domain] Litigation Case [Axis] Litigation Case [Axis] Trading Symbol Trading Symbol U.S. government-sponsored agency bonds US Government Agencies Debt Securities [Member] Options granted (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Fee receivable for reduction in royalty rate Collaborative Arrangement, Fee Receivable For Reduction In Royalty Rate Collaborative Arrangement, Fee Receivable For Reduction In Royalty Rate Advance Royalties [Abstract] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] New Accounting Pronouncements or Change in Accounting Principle [Table] Accounting Standards Update and Change in Accounting Principle [Table] Derivatives and Hedging Activities Derivatives, Reporting of Derivative Activity [Policy Text Block] Laura Williams [Member] Laura Williams Loan agreement covenant, net product revenue as percentage of outstanding loan balance, minimum Loan Agreement, Covenant, Net Product Revenue As Percentage Of Outstanding Loan Balance, Minimum Loan Agreement, Covenant, Net Product Revenue As Percentage Of Outstanding Loan Balance, Minimum Amortization and depreciation Deferred Tax Assets, Amortization and Depreciation Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from amortization and depreciation. Non-cash interest expense Amortization of Debt Discount (Premium) Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Remaining funding based on milestone achievement Remaining Funding Based On Conditional Milestone Achievement Remaining Funding Based On Conditional Milestone Achievement Stockholders’ equity: Equity, Attributable to Parent [Abstract] Potential commercialization milestones Collaborative Arrangement, Potential Commercialization Milestones Collaborative Arrangement, Potential Commercialization Milestones Schedule of Reconciliation of Unrecognized Tax Benefits Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block] Upfront payment Contract with Customer, Liability Schedule of Computation of Net Loss Per Common Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Schedule of Noncurrent Inventory Schedule of Inventory, Noncurrent [Table Text Block] Executive Category: Executive Category [Axis] Number of RSUs Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Options exercised (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Level 1 Fair Value, Inputs, Level 1 [Member] Deferred tax assets net of valuation allowance Deferred Tax Assets, Net of Valuation Allowance Schedule of Property and Equipment Property, Plant and Equipment [Table Text Block] Equity Components [Axis] Equity Components [Axis] Research and development tax credit Research Tax Credit Carryforward [Member] Financial Instruments [Domain] Financial Instruments [Domain] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Accrued and other liabilities Increase (Decrease) in Accrued Liabilities Potential common shares that would have been included if not for anti-dilutive effect of securities Potential Common Shares, Anti-Dilutive Effect On Securities Potential Common Shares, Anti-Dilutive Effect On Securities 2025 Long-Term Debt, Maturity, Year Two Options granted (shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Entity Small Business Entity Small Business Closing fee Debt Instrument, Closing Fee Amount Debt Instrument, Closing Fee Amount Local Phone Number Local Phone Number Total cash equivalents and investments, Gross Unrealized Losses Cash Cash Equivalents And Investments Gross Unrealized Losses Cash, cash equivalents and investments gross unrealized losses. Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Percentage of royalty revenue Percentage Of Royalty Revenue Represents percentage of royalty revenue. Accrued non-clinical research and development expenses Accrued Non-Clinical Research And Development Expenses Accrued Non-Clinical Research And Development Expenses Measurement Frequency [Axis] Measurement Frequency [Axis] RSUs Restricted stock units Restricted Stock Units (RSUs) [Member] Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Depreciation and amortization expense Depreciation Aggregate Intrinsic Value Stock Options, Aggregate Intrinsic Value [Abstract] Stock Options, Aggregate Intrinsic Value Cardinal Cardinal Health [Member] Cardinal Health Arrangements and Non-arrangement Transactions [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Decrease for revenue recognized for product supply Contract With Customer, Liability, Revenue Recognized Cash Not Received, Current Contract With Customer, Liability, Revenue Recognized Cash Not Received, Current Commercial customers Accounts Receivable, Commercial Customer [Member] Accounts Receivable, Commercial Customer Taxes paid for net share settlement of equity awards Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation Fair Value by Liability Class [Domain] Fair Value by Liability Class [Domain] Transaction costs Contract With Customer, Liability, Transaction Costs Contract With Customer, Liability, Transaction Costs Schedule of Anti-Dilutive Securities Not Considered in Diluted Net Loss Per Common Share Calculation Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Gross To Net Sales Accrual And Reserve Classification [Axis] Gross To Net Sales Accrual And Reserve Classification [Axis] Gross To Net Sales Accrual And Reserve Classification IBSRELA Product, IBSRELA [Member] Product, IBSRELA Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Research and development Research and development expenses Research and Development Expense [Member] Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Anti-dilutive securities not included in computation of diluted net loss per share Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Award Type [Axis] Award Type [Axis] Number of shares granted Granted (shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Reconciliation of Unrecognized Tax Benefits Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] Potential development and commercialization milestones Collaborative Arrangement, Potential Development And Commercialization Milestones Represents the amount of future development and commercialization milestone under collaborative arrangements. Fair Value Hierarchy [Domain] Fair Value Hierarchy and NAV [Domain] ICFR Auditor Attestation Flag ICFR Auditor Attestation Flag General and administrative expense General and Administrative Expense [Member] Property and equipment, gross Property, Plant and Equipment, Gross Right-of-use assets obtained in exchange for lease obligations Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Imputed interest expenses Lessee, Operating Lease, Liability, Undiscounted Excess Amount PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Schedule of Components of Provision for Income Taxes Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Potential increase to shares reserved for inclusion of forfeited or unexercised options from prior plan Increase In Shares Reserved For Issuance, Maximum Shares To Be Issued Upon Inclusion Of Forfeited Or Unexercised Options Increase In Shares Reserved For Issuance, Maximum Shares To Be Issued Upon Inclusion Of Forfeited Or Unexercised Options Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Current portion of operating lease liability Current portion of lease liabilities Less: Current portion of operating lease liability Operating Lease, Liability, Current Licensing revenue License License [Member] Issuance of common stock under employee stock purchase plan (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Proceeds from maturities and redemptions of investments Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale 2026 Lessee, Operating Lease, Liability, to be Paid, Year Three Thereafter Long-Term Debt, Maturity, After Year Four Long-Term Debt, Maturity, After Year Four Accrued Expenses "Accrued Expenses, Policy [Policy Text Block] "Accrued Expenses, Policy Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Secured Overnight Financing Rate (SOFR) Secured Overnight Financing Rate (SOFR) [Member] Secured Overnight Financing Rate (SOFR) Number of defendants Loss Contingency, Number of Defendants Counterparty Name [Domain] Counterparty Name [Domain] 2025 Lessee, Operating Lease, Liability, to be Paid, Year Two Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Closing fee percentage Line of Credit Facility, Commitment Fee Percentage Deferred revenue Beginning balance Ending balance Contract with Customer, Liability, Current Schedule of Valuation Assumptions for Stock Options Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Security Exchange Name Security Exchange Name Investment in continuous unrealized loss position for more than one year Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions Selling, general and administrative Selling, General and Administrative Expense Accumulated other comprehensive income (loss) Accumulated Other Comprehensive Income (Loss), Net of Tax Collaboration and Licensing Agreements Collaborative Arrangement Disclosure [Text Block] Stock options Options to purchase common stock Employee Stock Option [Member] Derivative Liabilities Derivative Instruments and Hedging Activities Disclosure [Text Block] Total operating expenses Costs and Expenses Maximum Maximum [Member] Unrecognized Compensation Expense Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Document Type Document Type Potential increase in shares reserved as a percentage of shares outstanding Increase In Shares Reserved For Issuance, Option For Annual Increase As Percentage Of Shares Outstanding Increase In Shares Reserved For Issuance, Option For Annual Increase As Percentage Of Shares Outstanding Tabular List, Table Tabular List [Table Text Block] Prepaid commercial manufacturing Prepaid Commercial Manufacturing, Current Prepaid Commercial Manufacturing, Current Inventory Inventory, Policy [Policy Text Block] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Minimum tax credit carryforwards Minimum Tax Credit Carryforward [Member] Minimum Tax Credit Carryforward [Member] Equity Incentive Plans Share-Based Payment Arrangement [Text Block] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Other, net Other Noncash Income (Expense) Number of options to extend Lessee, Operating Lease, Number Of Renewal Options Lessee, Operating Lease, Number Of Renewal Options Derivative [Table] Derivative [Table] Customer Customer Concentration Risk [Member] Variable Rate [Axis] Variable Rate [Axis] Cash Cash [Member] Options canceled (shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Title of 12(b) Security Title of 12(b) Security Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Amounts invoiced as prepayments for product supply Contract With Customer, Liability, Revenue Invoiced As Prepayments For Product Supply, Noncurrent Contract With Customer, Liability, Revenue Invoiced As Prepayments For Product Supply, Noncurrent Short-term investments: Debt Securities, Available-for-Sale, Fair Value to Amortized Cost, after Allowance for Credit Loss [Abstract] Sublease Income Sublease Income Threshold percentage of net sales for tiered royalties Threshold Percentage of Sales For Tiered Royalties Represents the threshold percentage of net sales for tiered royalties. Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Nonvested balance, beginning (in dollars per share) Nonvested balance, ending (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Foreign withholding tax Effective Income Tax Rate Reconciliation, Foreign Withholding Tax, Percent Effective Income Tax Rate Reconciliation, Foreign Withholding Tax, Percent Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Entity Tax Identification Number Entity Tax Identification Number 2023 Open Market Sales Agreement Open Market Sales Agreement 2023, At The Market Offering [Member] Open Market Sales Agreement 2023, At The Market Offering Exit fee, term (in years) Loan Agreement, Exit Fee, Term Loan Agreement, Exit Fee, Term Accrued sales and marketing expenses Accrued Sales And Marketing Expenses Amount of accrued sales and marketing expenses. Statistical Measurement [Axis] Statistical Measurement [Axis] Entity Interactive Data Current Entity Interactive Data Current Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Fosun Pharma Shanghai Fosun Pharmaceutical Industrial Development [Member] Represents Shanghai Fosun Pharmaceutical Industrial Development. Debt Securities, Available-for-sale [Table] Debt Securities, Available-for-Sale [Table] Reclassify amounts to be recognized in the next twelve months Contract With Customer, Liability, Revenue To Be Recognized In Next Twelve Months Contract With Customer, Liability, Revenue To Be Recognized In Next Twelve Months Product sales, net Product [Member] Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Knight Agreement License Agreement Development Commercialization Distribution In Canada [Member] Agreement for the development, commercialization and distribution fo tenapanor in Canada. The Knight Agreement. Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Measure: Measure [Axis] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Name Outstanding Recovery, Individual Name Product Sales, Net and Reserves for Variable Consideration and Collaboration Revenue Recognition Revenue from Contract with Customer [Policy Text Block] Bioridge Phama Bioridge Phama [Member] Bioridge Phama Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Schedule of Components of Deferred Tax Assets Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Counterparty Name [Axis] Counterparty Name [Axis] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Cash paid for operating lease Operating Lease, Payments Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Components of the provision for income taxes Income Tax Expense (Benefit), Continuing Operations [Abstract] Weighted-average share price (in dollars per share) Sale Of Stock, Weighted-Average Price Per Share Sale Of Stock, Weighted-Average Price Per Share Operating lease, impairment loss Operating Lease, Impairment Loss Non-cash interest expense related to the sale of future royalties Amortization of the deferred royalty obligation Amortization of Advance Royalty PEO PEO [Member] Concentration of Credit Risk Concentration Risk, Credit Risk, Policy [Policy Text Block] Auditor Location Auditor Location Beginning balance (in shares) Ending balance (in shares) Shares, Outstanding Upfront payment received Proceeds from License Fees Received Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Sale of Stock [Axis] Sale of Stock [Axis] Non-cash Interest Expense on Deferred Royalty Obligation Non Cash Interest Expense On Deferred Royalty Obligation [Policy Text Block] Non Cash Interest Expense On Deferred Royalty Obligation Net cash (used in) provided by investing activities Net Cash Provided by (Used in) Investing Activities Debt Instrument [Axis] Debt Instrument [Axis] Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Deferred royalty obligation Deferred Tax Assets, Royalty Obligation Deferred Tax Assets, Royalty Obligation Schedule of Future Debt Payment Obligations Schedule of Maturities of Long-Term Debt [Table Text Block] Total liabilities Liabilities Total current Current Income Tax Expense (Benefit) Percentage of non royalty revenue Percentage Of Non-Royalty Revenue Represents percentage of non-royalty revenue. Expected volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Common stock reserved for future issuance (in shares) Common Stock, Capital Shares Reserved for Future Issuance Fair Value, Measurement Frequency [Domain] Measurement Frequency [Domain] Property and Equipment, Net Property, Plant and Equipment Disclosure [Text Block] Title of Individual [Axis] Title of Individual [Axis] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] North America North America [Member] Long-Lived Tangible Asset [Domain] Long-Lived Tangible Asset [Domain] Robert Blanks [Member] Robert Blanks Exit fee (percent) Exit Fee, Percentage Exit Fee, Percentage Total of gross proceeds Equity Sales Agreement, Proceeds From Shares Issued Since Inception Equity Sales Agreement, Proceeds From Shares Issued Since Inception Offering sales commission (percent) Stock Issuance Cost, Commission, Percent Percentage of commission given on gross proceeds from sale of securities. Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] State Current State and Local Tax Expense (Benefit) Total current assets Assets, Current Accrued contract manufacturing expenses Accrued Contract Manufacturing Costs Accrued contract manufacturing costs. Schedule of Revenue from Customers as a Percentage of Total Product Revenue, Net Schedule of Revenues from Customers and Collaboration Partnerships Schedules of Concentration of Risk, by Risk Factor [Table Text Block] Supplementary disclosure of cash flow information: Supplemental Cash Flow Information [Abstract] Other states Tax Authority, States Other Than California [Member] Tax Authority, States Other Than California AstraZeneca Astrazeneca [Member] Represents information pertaining to AstraZeneca. Net Loss per Share Earnings Per Share, Policy [Policy Text Block] 2014 Plan Two Thousand Fourteen Equity Incentive Award Plan [Member] 2014 Equity Incentive Award Plan [Member] Number of payment tranches for fee receivable for reduction in royalty rate Collaborative Arrangement, Fee Receivable For Reduction In Royalty Rate, Number Of Payment Tranches Collaborative Arrangement, Fee Receivable For Reduction In Royalty Rate, Number Of Payment Tranches Concentration risk (percent) Concentration Risk, Percentage Estimated fair value Fair value of exit fee derivative liabilities, beginning Fair value of exit fee derivative liabilities, ending Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Current: Current Income Tax Expense (Benefit), Continuing Operations [Abstract] State taxes, net of federal benefit Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent Granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Asset-backed securities Asset-Backed Securities [Member] Accounts Receivable Accounts Receivable [Policy Text Block] Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Options exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Additional committed capital Line Of Credit Facility, Accordion Feature, Additional Committed Capital Line Of Credit Facility, Accordion Feature, Additional Committed Capital Class of Stock [Axis] Class of Stock [Axis] 2018 Term Loan Term Loan 2018 [Member] Term Loan 2018 Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Less: Unaccreted value of final fee Debt Instrument, Fee Amount After second anniversary to maturity date Debt Instrument, Redemption, Period Three [Member] Fosun Agreement License Agreement Development Commercialization Distribution In China [Member] Agreement for the development, commercialization and distribution of tenapanor in China. The Fosun Agreement. Depreciation and amortization expense Depreciation, Depletion and Amortization Issuance of derivative in connection with issuance of loan payable Derivative Issued Represents the non-cash issuance of derivative in connection with issuance of loan payable. Schedule of Chargebacks, Discounts and Reserve Balances Schedule Of Gross To Net Sales Accruals [Table Text Block] Schedule Of Gross To Net Sales Accruals Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Exit fee, net product revenue threshold Loan Agreement, Exit Fee, Net Product Revenue Threshold Metric, Trailing Six Month Basis, Minimum Loan Agreement, Exit Fee, Net Product Revenue Threshold Metric, Trailing Six Month Basis, Minimum Commercial paper Commercial Paper [Member] Cash and short-term investments Total cash equivalents and investments, Fair Value Investments and Cash Deferred revenue Increase (Decrease) in Deferred Revenue Valuation allowance Deferred Tax Assets, Valuation Allowance Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Axis] Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued 2021 Open Market Sales Agreement Open Market Sales Agreement 2021, At The Market Offering [Member] Open Market Sales Agreement 2021, At The Market Offering Entity Emerging Growth Company Entity Emerging Growth Company Finished goods Inventory, Finished Goods, Gross Gross deferred tax assets Deferred Tax Assets, Gross Office equipment and furniture Office Equipment And Furniture [Member] Office Equipment And Furniture [Member] Potential development milestones Collaborative Arrangement, Potential Development Milestones Collaborative Arrangement, Potential Development Milestones 2024 Lessee, Operating Lease, Liability, to be Paid, Year One Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Title Trading Arrangement, Individual Title Common Stock Common Stock [Member] Individual: Individual [Axis] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Income Statement Location [Domain] Income Statement Location [Domain] Payments for the 2018 Loan, net of costs Repayments of Secured Debt Schedule of Changes in Fair Value of Derivative Liabilities Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Minimum Minimum [Member] Property and equipment, net Total property and equipment, net Property, Plant and Equipment, Net Healthcare royalty partners IV, L.P HealthCare Royalty Partners IV, L.P [Member] HealthCare Royalty Partners IV, L.P Office space area (sq ft) Area of Real Estate Property Weighted Average Remaining Contractual Term (in Years) Stock Options, Weighted Average Remaining Contractual Term [Abstract] Stock Options, Weighted Average Remaining Contractual Term Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Assets Assets [Abstract] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Accrued professional and consulting services Accrued Professional And Consultant Fees Current Accrued professional and consultant fees current. Rebates, Wholesaler and GPO Fees Contract With Customer, Rebates, Wholesaler And GPO Fees [Member] Contract With Customer, Rebates, Wholesaler And GPO Fees Operating lease liabilities Increase (Decrease) in Operating Lease Liability Payments for taxes related to net share settlement of equity awards Payment, Tax Withholding, Share-Based Payment Arrangement Deferred tax assets: Deferred Tax Assets, Net [Abstract] Other Deferred Tax Assets, Other U.S. treasury securities US Treasury Securities [Member] Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Sale of property, plant and equipment Property, Plant and Equipment, Disposals Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Accumulated Deficit Retained Earnings [Member] Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Net loss per share of common stock - basic (in dollars per share) Net loss per share - basic (in dollars per share) Earnings Per Share, Basic Issuance of common stock under employee stock purchase plan Stock Issued During Period, Value, Employee Stock Purchase Plan Accounting Policies [Abstract] Accounting Policies [Abstract] Sale of Stock [Domain] Sale of Stock [Domain] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Knight Knight Therapeutics Inc [Member] Represents information pertaining to Knight Therapeutics Inc. Net deferred tax assets Deferred Tax Assets, Net Officer Trading Arrangement [Member] Officer Trading Arrangement Intrinsic value of options exercised Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value Strezsak v. Ardelyx, Inc. Strezsak Versus Ardelyx, Inc. [Member] Strezsak Versus Ardelyx, Inc. Issuance of common stock for services Stock Issued Issuance of common stock for services Stock Issued During Period, Value, Issued for Services Document Transition Report Document Transition Report Award Timing Predetermined Award Timing Predetermined [Flag] ISBRELA And XPHOZAH Units, Previously Expensed In Period Prior To Commencement Of Capitalization Of Inventory Costs ISBRELA And XPHOZAH Units, Previously Expensed In Period Prior To Commencement Of Capitalization Of Inventory Costs [Member] ISBRELA And XPHOZAH Units, Previously Expensed In Period Prior To Commencement Of Capitalization Of Inventory Costs Collaboration and Licensing Agreements Collaboration and Licensing Agreements [Abstract] Accounts payable Increase (Decrease) in Accounts Payable Entity Public Float Entity Public Float Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Property, Plant and Equipment [Abstract] Property, Plant and Equipment [Abstract] Derivative Instrument [Axis] Derivative Instrument [Axis] Increase in valuation allowance Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount Principal outstanding Total repayment obligations Long-Term Debt, Gross 2008 Plan Two Thousand Eight Stock Incentive Plan [Member] Two Thousand Eight Stock Incentive Plan [Member] Liability Class [Axis] Liability Class [Axis] All Trading Arrangements All Trading Arrangements [Member] All Adjustments to Compensation All Adjustments to Compensation [Member] Compensation Amount Outstanding Recovery Compensation Amount Discounts and Chargebacks Contract With Customer, Discounts And Chargebacks [Member] Contract With Customer, Discounts And Chargebacks Forfeited (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Total deferred Deferred Income Tax Expense (Benefit) Subsequent Event Type [Axis] Subsequent Event Type [Axis] Reclassify amounts to be recognized in the next twelve months Contract With Customer, Liability, Decrease In Revenue, To Be Recognized In Next Twelve Months Contract With Customer, Liability, Decrease In Revenue, To Be Recognized In Next Twelve Months Income Tax Disclosure [Line Items] Income Tax Disclosure [Line Items] Income Tax Disclosure [Line Items] Upfront license fees Collaboration And Licensing Agreements, Upfront License Fees Collaboration And Licensing Agreements, Upfront License Fees Options canceled (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Document Financial Statement Error Correction [Flag] Document Financial Statement Error Correction [Flag] Forfeited (shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period 2024 Long-Term Debt, Maturity, Year One Common stock closing price (in dollars per share) Share Price Prior to first anniversary of closing date Debt Instrument, Redemption, Period One [Member] Proceeds from sale of property and equipment Proceeds from Sale of Property, Plant, and Equipment Documents Incorporated by Reference Documents Incorporated by Reference [Text Block] Tax credits Effective Income Tax Rate Reconciliation, Tax Credit, Percent Document Period End Date Document Period End Date Adoption Date Trading Arrangement Adoption Date Revenue Revenue from Contract with Customer Benchmark [Member] Contingent liabilities Loss Contingency Accrual Gain on disposition of property plant equipment Gain (Loss) on Disposition of Property Plant Equipment Provision for income taxes Provision for income taxes Income Tax Expense (Benefit) Total cash equivalents and investments, Gross Unrealized Gains Cash Cash Equivalents And Investments Gross Unrealized Gains Cash, cash equivalents and investments gross unrealized gains. Fair Value Measurements Fair Value Disclosures [Text Block] Amortization, effective interest rate, percent Contract With Customer, Liability, Amortization, Effective Interest Rate, Percent Contract With Customer, Liability, Amortization, Effective Interest Rate, Percent Number of operating segments Number of Operating Segments Cash and Cash Equivalents [Abstract] Cash and Cash Equivalents [Abstract] Prepaid commercial manufacturing Increase (Decrease) In Prepaid Commercial Manufacturing Expense Increase (Decrease) In Prepaid Commercial Manufacturing Expense Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-Sale [Line Items] Inventory Inventory Disclosure [Text Block] Weighted-average remaining life (years) Operating Lease, Weighted Average Remaining Lease Term Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Money market funds Money Market Funds [Member] Schedule of Valuation Assumptions for Employee Stock Purchase Plan Schedule of Share-Based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block] Tax credit carryforwards Tax Credit Carryforward, Amount Cash and cash equivalents Fair value Cash and Cash Equivalents, at Carrying Value Total cash equivalents and investments, Cost Investments And Cash, Amortized Cost Investments And Cash, Amortized Cost Floating per annum rate (percent) Debt Instrument, Basis Spread on Variable Rate Estimated useful lives Property, Plant and Equipment, Useful Life Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Change in valuation allowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent McKesson Corporation McKesson McKesson Corporation [Member] McKesson Corporation Go v. Raab Go Versus Raab [Member] Go Versus Raab Schedule of Deferred Revenue Balances Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] Deferred Royalty Obligation Related To The Sale Of Future Royalties Asset Retirement Obligation Disclosure [Text Block] Revenue Revenue from Contract with Customer [Text Block] Additional paid-in capital Additional Paid in Capital, Common Stock Additional Paid-In Capital Additional Paid-in Capital [Member] Document Annual Report Document Annual Report Gross-to-net sales accruals and reserves Contract With Customer, Gross To Net Sales Accrual [Roll Forward] Contract With Customer, Gross To Net Sales Accrual Contingencies [Line Items] Loss Contingencies [Line Items] Cover [Abstract] Cover [Abstract] Commercial paper Commercial Paper, Not Included with Cash and Cash Equivalents [Member] United States UNITED STATES Tax Credit Carryforward, Name [Domain] Tax Credit Carryforward, Name [Domain] Recurring Fair Value, Recurring [Member] Total undiscounted operating lease payments Lessee, Operating Lease, Liability, to be Paid Payment to be received Revenue, Remaining Performance Obligation, Amount Subsidiary, Sale of Stock [Line Items] Subsidiary, Sale of Stock [Line Items] Net (decrease) increase in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Income Tax Authority, Name [Domain] Income Tax Authority, Name [Domain] Term of lease extension Lessee, Operating Lease, Renewal Term Equity Component [Domain] Equity Component [Domain] State State and Local Jurisdiction [Member] Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Other Deferred Tax Liabilities, Other Entity Current Reporting Status Entity Current Reporting Status Concentration Risk Type [Domain] Concentration Risk Type [Domain] Loss from operations Operating Income (Loss) Derivative liability for exit fees Derivative Liability for Exit Fees Amount of derivative liability for exit fee. METiS Therapeutics Inc METiS Therapeutics Inc [Member] METiS Therapeutics Inc 2022 Exit Fee Exit Fee 2022 [Member] Exit Fee 2022 Cash, Cash Equivalents and Short-Term Investments Cash, Cash Equivalents, and Short-Term Investments [Text Block] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Kyowa Kirin Kkc [Member] Represents the information pertaining to KKC. Property and Equipment Property, Plant and Equipment, Policy [Policy Text Block] Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Changes in estimated fair value: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Variable Rate [Domain] Variable Rate [Domain] Pay vs Performance Disclosure [Line Items] Entity Voluntary Filers Entity Voluntary Filers Executive compensation disallowed under IRC Sec 162(m) Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Executive Compensation Disallowed IRC Sec 162m, Percent Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Executive Compensation Disallowed IRC Sec 162m, Percent Statistical Measurement [Domain] Statistical Measurement [Domain] Agreed amount for exit fee upon occurrence of certain conditions Agreed amount for exit fee upon change of control or regulatory approval Derivative Liability, Notional Amount Underlying Security Market Price Change Underlying Security Market Price Change, Percent Share of common stock subject to issued inducement grants Common Stock Subject To Issued Inducement Grants, Shares Common Stock Subject To Issued Inducement Grants, Shares Additional default interest rate Debt Instrument, Interest Rate On Default, Percentage Percentage of additional default interest rate on the event of default. Nonvested balance, beginning (shares) Nonvested balance, ending (shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Borrowing Debt Disclosure [Text Block] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Summary of Additional Details of the Leases Schedule of Additional Details of Leases [Table Text Block] The tabular disclosure of additional details of the leases. Research and Development Costs Research and Development Expense, Policy [Policy Text Block] Schedule of Securities Classified as Cash, Cash Equivalents and Short-Term Investments Cash, Cash Equivalents and Investments [Table Text Block] MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Accounts payable Accounts Payable, Current Options exercisable (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Restatement Determination Date: Restatement Determination Date [Axis] Corporate bonds Corporate Debt Securities [Member] Other income, net Nonoperating Income (Expense) Income tax at the federal statutory rate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Commitments and contingencies (Note 20) Commitments and Contingencies Undiscounted cash payment obligations Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract] Proceeds from issuance of common stock in at the market offering, net of issuance costs Proceeds from issuance of common stock in at the market offering, net of issuance costs Proceeds from Issuance of Common Stock Geographical [Axis] Geographical [Axis] Current portion of long-term debt Less: Current portion of long-term debt Loans Payable, Current Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Income Taxes Income Tax Disclosure [Text Block] Concentration Risk [Line Items] Concentration Risk [Line Items] Leases Lessee, Leases [Policy Text Block] Copay and Returns Contract With Customer, Copay And Returns [Member] Contract With Customer, Copay and Returns Waltham, Massachusetts Waltham, Massachusetts [Member] Waltham, Massachusetts Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Weighted-Average Grant Date Fair Value Per Share Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] PEO Total Compensation Amount PEO Total Compensation Amount Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Options vested and expected to vest (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Level 3 Fair Value, Inputs, Level 3 [Member] Options issued and outstanding balance, beginning (shares) Options issued and outstanding balance, ending (shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Issuance of common stock upon exercise of options Stock Issued During Period, Value, Stock Options Exercised Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Beginning balance Ending balance Contract With Customer, Gross To Net Sales Accruals Contract With Customer, Gross To Net Sales Accruals Weighted-average grant-date estimated fair value of options granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Net loss Net loss Net loss Net Income (Loss) Total current liabilities Liabilities, Current Derivative Contract [Domain] Derivative Contract [Domain] Foreign Currency Foreign Currency Transactions and Translations Policy [Policy Text Block] Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Company Selected Measure Name Company Selected Measure Name Leases Lessee, Operating Leases [Text Block] Kyowa Kirin Co. Ltd Kyowa Kirin Co. Ltd [Member] Represents the information pertaining to Kyowa Kirin Co., Ltd. Liabilities and stockholders’ equity Liabilities and Equity [Abstract] Debt Instrument, Redemption, Period [Axis] Debt Instrument, Redemption, Period [Axis] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Gross Unrealized Losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Issuance of common stock upon exercise of options (in shares) Options exercised (shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Inventory Inventory, Gross Total cost of goods sold Cost of Goods and Services Sold Vesting period (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Number of lease agreements Number of Operating Lease Arrangements Represents the number of operating lease arrangements. Summary of significant accounting policies New Accounting Pronouncements or Change in Accounting Principle [Line Items] Name Measure Name Name Forgone Recovery, Individual Name Loan agreement, covenant, cash and cash equivalents as percentage of outstanding loan balance, calculation period Loan Agreement, Covenant, Cash And Cash Equivalents As Percentage Of Outstanding Loan Balance, Calculation Period Loan Agreement, Covenant, Cash And Cash Equivalents As Percentage Of Outstanding Loan Balance, Calculation Period Purchases of investments Payments to Acquire Short-Term Investments Additions based on tax positions related to prior year Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions Thereafter Lessee, Operating Lease, Liability, to be Paid, after Year Three Lessee, Operating Lease, Liability, to be Paid, after Year Three Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Underlying Securities Award Underlying Securities Amount Accounts receivable Increase (Decrease) in Accounts Receivable Selling, general and administrative Selling, General and Administrative Expenses [Member] Stock based compensation Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Percent 2018 Exit Fee payment Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements Operating lease liability, net of current portion Operating lease liability, net of current portion Operating Lease, Liability, Noncurrent Royalty payments and commercial milestone payments Increase (Decrease) in Royalties Payable Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Change in Fair Value of Derivative Liability Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Income Statement Location [Axis] Income Statement Location [Axis] Less: Unamortized discount and debt issuance costs Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net Accrued payments due to AstraZeneca Accrued Payments Due To Third-Party Accrued Payments Due To Third-Party U.S. government-sponsored agency bonds US Government Corporations and Agencies Securities [Member] Summary of Undiscounted Cash Payment Obligations for Operating Lease Liabilities Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Cash and Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Cost of Goods Sold Cost of Goods and Service [Policy Text Block] Payables and Accruals [Abstract] Payables and Accruals [Abstract] Products and Services [Domain] Product and Service [Domain] Other Performance Measure, Amount Other Performance Measure, Amount Proceeds from loan payable, net of issuance costs Proceeds from Debt, Net of Issuance Costs Summary of Lease Costs Lease, Cost [Table Text Block] Payment of the 2018 Exit Fee Payments for Derivative Instrument, Financing Activities Inventory Increase (Decrease) in Inventories Unrealized gains (losses) on available-for-sale securities Unrealized gains (losses) on available-for-sale securities Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent Investing activities Net Cash Provided by (Used in) Investing Activities [Abstract] Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Instruments and Hedging Activities Disclosure [Abstract] Plan Name [Domain] Plan Name [Domain] Cost of goods sold: Cost of Goods and Services Sold [Abstract] Interest expense Interest Expense AmerisourceBergen Drug Corporation AmerisourceBergen Drug Corporation [Member] AmerisourceBergen Drug Corporation Number of shares initially authorized (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Options issued and outstanding (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Stockholders' Equity Note [Abstract] Stockholders' Equity Note [Abstract] Trading Arrangement: Trading Arrangement [Axis] Use of Estimates Use of Estimates, Policy [Policy Text Block] Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Entity File Number Entity File Number Loss Contingencies [Table] Loss Contingencies [Table] Lease Arrangements [Axis] Lease Arrangements [Axis] Lease Arrangements Schedule of Restricted Stock Units Activity Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] California California Franchise Tax Board [Member] 2026 Long-Term Debt, Maturity, Year Three Allowance for credit loss on available-for-sale debt securities Debt Securities, Available-for-Sale, Allowance for Credit Loss Subtractions based on tax positions related to prior year Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions Auditor Firm ID Auditor Firm ID Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Gross To Net Sales Accrual And Reserve Classification [Domain] Gross To Net Sales Accrual And Reserve Classification [Domain] Gross To Net Sales Accrual And Reserve Classification [Domain] Entity Shell Company Entity Shell Company Restatement Determination Date Restatement Determination Date Waltham facility Facility Two, Waltham Massachusetts [Member] Facility Two, Waltham Massachusetts Additions based on tax positions related to current year Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Schedule of Restructuring and Related Costs [Table] Schedule of Restructuring and Related Costs [Table] Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Asset Class [Axis] Asset Class [Axis] 2022 Term Loan Term Loan 2022 [Member] Term Loan 2022 Term loan Loans Payable [Member] Denominator: Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Operating lease expense Operating Lease, Cost Impairment of Long-Lived Assets Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] Common stock, shares issued (in shares) Common Stock, Shares, Issued Number of shares vested Vested (shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Long-term debt Long-Term Debt Assets, fair value Assets, Fair Value Disclosure 2027 Long-Term Debt, Maturity, Year Four Common stock Common Class A [Member] Average Remaining Vesting Period (Years) Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Long-term debt, net of current portion Loans Payable, Noncurrent Federal Domestic Tax Authority [Member] Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Accrued expenses and other current liabilities Total accrued expenses and other current liabilities Accrued Liabilities and Other Liabilities Receivable Type [Axis] Receivable Type [Axis] Weighted-Average Exercise Price  per Share Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Subsequent event Subsequent Event [Member] Net operating loss carryforwards Operating Loss Carryforwards Other Other Liabilities, Current Income Statement [Abstract] Income Statement [Abstract] Prepayment premium (as a percent) Debt Instrument, Prepayment Fee, Percentage The percentage of fee payable on prepayment of debt. Issuance of common stock in at the market offering (in shares) Common stock sold and issued (in shares) Stock Issued During Period, Shares, New Issues Short-term securities, contractual maturities, maximum Available-For-Sale Securities, Debt Securities, Current, Contractual Maturities, Maximum Available-For-Sale Securities, Debt Securities, Current, Contractual Maturities, Maximum U.S. treasury securities US Treasury Notes Securities [Member] Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] 2020 Open Market Sales Agreement Open Market Sales Agreement 2020, At The Market Offering [Member] Open Market Sales Agreement 2020, At The Market Offering Numerator: Net Income (Loss) Attributable to Parent [Abstract] Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Additional details Lessee, Operating Lease, Description [Abstract] Total Inventory, Net Inventory, non-current Inventory, Noncurrent Financial Instrument [Axis] Financial Instrument [Axis] Total Shareholder Return Amount Total Shareholder Return Amount Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Supplementary disclosure of non-cash activities: Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Inventory Disclosure [Abstract] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Additional uncommitted capital Line Of Credit Facility, Accordion Feature, Additional Uncommitted Capital Line Of Credit Facility, Accordion Feature, Additional Uncommitted Capital Accumulated deficit Accumulated deficit Retained Earnings (Accumulated Deficit) Accrued gross to net revenue liabilities Accrued Gross To Net Revenue Liabilities Accrued Gross To Net Revenue Liabilities Term loan amount Debt Instrument, Face Amount Deferred tax liabilities: Deferred Tax Liabilities, Net [Abstract] Current assets: Assets, Current [Abstract] Leases [Abstract] Leases [Abstract] Entity Address, State or Province Entity Address, State or Province Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Schedule of Revenues from External Customers and Long-Lived Assets [Table] Schedule of Revenues from External Customers and Long-Lived Assets [Table] ESPP ESPP shares issuable Employee Stock Purchase Plan [Member] Employee Stock Purchase Plan [Member] Operating activities Net Cash Provided by (Used in) Operating Activities [Abstract] Aggregate cost of revenue recognized Cost Of Revenue, Aggregate Amount Recognized Cost of revenue, aggregate amount recognized. AZ Termination Agreement AstraZeneca Termination Agreement [Member] AstraZeneca Termination Agreement Asset Class [Domain] Asset Class [Domain] Fremont facility Facility, Fremont California [Member] Facility, Fremont California Other Effective Income Tax Rate Reconciliation, Other Adjustments, Percent Class of Stock [Domain] Class of Stock [Domain] Customer [Domain] Customer [Domain] Schedule of Current Inventory Schedule of Inventory, Current [Table Text Block] Revenues from External Customers and Long-Lived Assets [Line Items] Revenues from External Customers and Long-Lived Assets [Line Items] Number of Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Income tax provision Effective Income Tax Rate Reconciliation, Percent Operating lease, liability Total operating lease liabilities Operating Lease, Liability Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Geographic Information and Concentrations Geographic Information And Concentrations [Text Block] The entire disclosure on geographic information and concentrations. Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Accumulated Other Comprehensive (Loss) Income AOCI Attributable to Parent [Member] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount All Executive Categories All Executive Categories [Member] Deferred revenue, non-current Beginning balance Ending balance Contract with Customer, Liability, Noncurrent Plan Name [Axis] Plan Name [Axis] Debt Disclosure [Abstract] Debt Disclosure [Abstract] Facilities - right-of-use assets and lease liabilities Assets and Liabilities, Lessee [Abstract] Product supply revenue Product Supply Revenue [Member] Product Supply Revenue Earnings Per Share [Abstract] Earnings Per Share [Abstract] Common stock, $0.0001 par value; 500,000,000 and 300,000,000 shares authorized; 232,453,190 and 198,575,016 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively. Common Stock, Value, Issued Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Non-cash lease expense Operating Lease, Right-of-Use Asset, Periodic Reduction Sublease Facility, Fremont California Sublease Facility, Fremont California [Member] Sublease Facility, Fremont California Deferred: Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract] Audit Information [Abstract] Audit Information Collaborative development revenue Collaborative Development [Member] Collaborative Development [Member] Revenue from Contract with Customer [Abstract] All Individuals All Individuals [Member] Litigation Case [Domain] Litigation Case [Domain] Proceeds from the sale of future royalties, net of issuance costs Proceeds From Sale Of Future Royalties, Net Of Issuance Costs Proceeds From Sale Of Future Royalties, Net Of Issuance Costs Entity Filer Category Entity Filer Category Proceeds from 2022 Loan, net of issuance costs Proceeds from Issuance of Secured Debt Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Final fee due upon maturity, acceleration, prepayment, or termination (percent) Debt Instrument, Fee Due Upon Maturity, Acceleration, Prepayment, Termination, Percentage Debt Instrument, Fee Due Upon Maturity, Acceleration, Prepayment, Termination, Percentage Statement [Table] Statement [Table] Current Fiscal Year End Date Current Fiscal Year End Date Fair value analysis, percentage change in probability of occurrence Fair Value Sensitivity Analysis, Change In Probability Of Occurrence, Percentage Fair Value Sensitivity Analysis, Change In Probability Of Occurrence, Percentage Schedule of Reconciliation of Effective Tax Rate Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Balance at beginning of year Balance at end of year Unrecognized Tax Benefits Proceeds from milestone payments Revenue, Remaining Performance Obligation, Variable Consideration Amount Revenue, Remaining Performance Obligation, Variable Consideration Amount Income Tax Authority [Axis] Income Tax Authority [Axis] PEO Name PEO Name Asia Pacific Asia Pacific [Member] Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Stock-based compensation Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost Short-term investments Debt Securities, Available-for-Sale, Current Non-Current Change In Contract With Customer Liability, Noncurrent, Rollforward [Roll Forward] Change In Contract With Customer Liability, Noncurrent, Rollforward Interest rate (as percent) Debt Instrument, Interest Rate, Stated Percentage Accrued compensation and benefits Increase (Decrease) in Employee Related Liabilities Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Term Loan A Term Loan 2022 A [Member] Term Loan 2022 A Total stockholders’ equity Beginning balance Ending balance Equity, Attributable to Parent 2017 KKC Agreement License Agreement Development Commercialization Distribution In Japan [Member] Agreement for the development, commercialization and distribution of tenapanor in Japan. The 2017 KKC Agreement. Concentration Risk Type [Axis] Concentration Risk Type [Axis] Expected term (years) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Loss before provision for income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Future payment obligations Long-Term Debt, Fiscal Year Maturity [Abstract] Fair Value Measurements Fair Value Measurement, Policy [Policy Text Block] Restructuring Restructuring and Related Activities Disclosure [Text Block] Number of lawsuits Loss Contingency, New Claims Filed, Number Level 2 Fair Value, Inputs, Level 2 [Member] Maximum shares to be issued upon exercise of incentive stock options Increase In Shares Reserved For Issuance, Maximum Shares To Be Issued Upon Exercise Of Stock Options Increase In Shares Reserved For Issuance, Maximum Shares To Be Issued Upon Exercise Of Stock Options Income Tax Disclosure [Table] Income Tax Disclosure [Table] Income Tax Disclosure [Table] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Document Fiscal Period Focus Document Fiscal Period Focus Options issued and outstanding balance, beginning (in dollars per share) Options issued and outstanding balance, ending (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Stock-based compensation Share-Based Payment Arrangement, Noncash Expense Schedule of Revenue by Geographic Areas Revenue from External Customers by Geographic Areas [Table Text Block] Foreign Foreign Tax Authority [Member] Provisions Contract With Customer, Gross To Net Sales, Provisions Contract With Customer, Gross To Net Sales, Provisions Lease Arrangements [Domain] Lease Arrangements [Domain] Lease Arrangements [Domain] City Area Code City Area Code Net Loss Per Share Earnings Per Share [Text Block] Product and Service [Axis] Product and Service [Axis] Document Fiscal Year Focus Document Fiscal Year Focus Geographical [Domain] Geographical [Domain] Stock-Based Compensation Compensation Related Costs, Policy [Policy Text Block] Organization and Basis of Presentation Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block] Schedule of Stock Option Activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Exercise Price Award Exercise Price Collaboration partnership concentration risk Collaboration Partnership Concentration Risk [Member] Collaboration Partnership Concentration Risk Liabilities, fair value Liabilities, Fair Value Disclosure Other cost of revenue Product and Service, Other [Member] Short-Term Investments Short Term Investments [Policy Text Block] Short term investments. Cash paid for income taxes Income Taxes Paid, Net 2022 Exit Fee addition at fair value Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases Net operating loss carryforwards, indefinite Operating Loss Carryforwards, Without Expiration Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws indefinitely. Schedule of Stock-Based Compensation Recognized Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Total liabilities and stockholders’ equity Liabilities and Equity Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost Other assets Other Assets, Noncurrent Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Risk-free interest rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Right-of-use assets Right-of-use assets Operating Lease, Right-of-Use Asset Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Foreign Current Foreign Tax Expense (Benefit) Arrangement Duration Trading Arrangement Duration Entity Address, City or Town Entity Address, City or Town Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Options vest and expected to vest (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term BioRidge Pharma, LLC BioRidge Pharma, LLC [Member] BioRidge Pharma, LLC Restructuring charges Restructuring Charges Termination Date Trading Arrangement Termination Date Common stock, shares authorized (in shares) Common Stock, Shares Authorized Fair Value Debt Securities, Available-for-Sale Raw materials Inventory, Raw Materials, Gross Accrued Expenses and Other Current Liabilities Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block] Gross Unrealized Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Current Change In Contract With Customer Liability, Current, Rollforward [Roll Forward] Change In Contract With Customer Liability, Current, Rollforward Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Prepaid commercial manufacturing, non-current Prepaid Commercial Manufacturing, Non Current Prepaid Commercial Manufacturing, Non Current Maximum shares to be issued under ESPP Share-Based Compensation Arrangement By Share-Based Payment Award, Maximum Number Of Shares Under Employee Stock Purchase Plan Share-Based Compensation Arrangement By Share-Based Payment Award, Maximum Number Of Shares Under Employee Stock Purchase Plan Derivative [Line Items] Derivative [Line Items] Award Timing Disclosures [Line Items] Relationship to Entity [Domain] Title of Individual [Domain] Floor Rate Secured Overnight Financing Rate (SOFR) Floor Rate [Member] Secured Overnight Financing Rate (SOFR) Floor Rate Collaborators Accounts Receivable, Collaborator [Member] Accounts Receivable, Collaborator Deferred royalty obligation related to the sale of future royalties Deferred Royalty Obligation, Noncurrent Deferred Royalty Obligation, Noncurrent Estimated fair value of RSUs vested Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value Term Loan C Term Loan 2022 C [Member] Term Loan 2022 C Derivative liabilities for exit fee Exit fee derivative liability Derivative Financial Instruments, Liabilities [Member] Gain on sale of equipment Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property Decrease for revenue recognized for product supply Contract With Customer, Liability, Revenue Recognized Cash Not Received, Noncurrent Contract With Customer, Liability, Revenue Recognized Cash Not Received, Noncurrent Maximum potential payment per agreement Collaborative Arrangement, Potential Payment Per Termination Agreement, Maximum Collaborative Arrangement, Potential Payment Per Termination Agreement, Maximum Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Income Taxes Income Tax, Policy [Policy Text Block] Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Work in process Inventory, Work in Process, Gross Debt Instrument, Redemption, Period [Domain] Debt Instrument, Redemption, Period [Domain] Insider Trading Arrangements [Line Items] Cash and cash equivalents: Cash and Cash Equivalents, at Carrying Value [Abstract] Options issued and outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Future obligation upon loan funding or other events Loan Agreement, Future Obligation Upon Funding Or Other Events Loan Agreement, Future Obligation Upon Funding Or Other Events Entity Registrant Name Entity Registrant Name Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Award Timing Method Award Timing Method [Text Block] Schedule of Total Unrecognized Stock-Based Compensation Expense, Net of Estimated Forfeitures Share-Based Payment Arrangement, Nonvested Award, Cost [Table Text Block] Adjustment to Compensation, Amount Adjustment to Compensation Amount Auditor Name Auditor Name Inducement Plan Two Thousand Sixteen Employment Commencement Incentive Plan [Member] 2016 Employment commencement incentive plan. Existence of option to extend Lessee, Operating Lease, Existence of Option to Extend [true false] Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Less: accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Schedule of Fair Value of Financial Assets and Liabilities Measured on a Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Options exercisable (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Credits/payments Contract With Customer, Gross To Credits Or Deductions Issued Contract With Customer, Gross To Credits Or Deductions Issued Entity Central Index Key Entity Central Index Key Liabilities: Liabilities, Fair Value Disclosure [Abstract] Accrued clinical expenses Accrued Clinical Expenses Accrued clinical expenses. Stock-based compensation Share-Based Payment Arrangement, Expense Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Income Tax Authority [Domain] Income Tax Authority [Domain] Accrued compensation and benefits Employee-related Liabilities, Current Proceeds from royalties received Proceeds from Royalties Received Name Trading Arrangement, Individual Name Loan agreement covenant, cash and cash equivalents as percentage of outstanding loan balance, minimum Loan Agreement, Covenant, Cash And Cash Equivalents As Percentage Of Outstanding Loan Balance, Minimum Loan Agreement, Covenant, Cash And Cash Equivalents As Percentage Of Outstanding Loan Balance, Minimum Prepaid commercial manufacturing Prepaid Commercial Manufacturing Prepaid Commercial Manufacturing Schedule of Revenue Disaggregation of Revenue [Table Text Block] Issuance of common stock in at the market offering Stock Issued During Period, Value, New Issues Risks and Uncertainties [Abstract] Total revenues Revenue from Contract with Customer, Excluding Assessed Tax Term Loan B Term Loan 2022 B [Member] Term Loan 2022 B Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Amendment Flag Amendment Flag Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Weighted-average discount rate Operating Lease, Weighted Average Discount Rate, Percent Cash paid for interest Interest Paid, Excluding Capitalized Interest, Operating Activities Assets: Assets, Fair Value Disclosure [Abstract] Issuance of common stock for services (in shares) Issuance of common stock for services (in shares) Stock Issued During Period, Shares, Issued for Services Leasehold improvements Leasehold Improvements [Member] Shares used in computing net loss per share - diluted (in shares) Weighted average common shares outstanding - diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Income Tax Authority, Name [Axis] Income Tax Authority, Name [Axis] Number of shares added to initial reserve Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized Operating expenses: Operating Expenses [Abstract] Gross product revenue Revenue, Product and Service Benchmark [Member] Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Company Selected Measure Amount Company Selected Measure Amount Lease costs Lease, Cost [Abstract] Total assets Assets Name Awards Close in Time to MNPI Disclosures, Individual Name Stock-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Restructuring and Related Activities [Abstract] Vested (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Non-NEOs Non-NEOs [Member] Term Loan D Term Loan 2022 D [Member] Term Loan 2022 D Right-of-use asset Deferred Tax Liabilities, Right Of Use Asset Amount of deferred tax liability attributable to taxable temporary differences from right of use asset. Financing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Non-PEO NEO Non-PEO NEO [Member] Adjustment to Compensation: Adjustment to Compensation [Axis] 2018 Exit Fee Exit Fee 2018 [Member] Exit Fee 2018 Tax credits Deferred Tax Assets, Tax Credit Carryforwards, Research Net operating loss carryforwards Deferred Tax Assets, Operating Loss Carryforwards Term Loans Debt Instrument [Line Items] Shares used in computing net loss per share - basic (in shares) Weighted average common shares outstanding - basic (in shares) Weighted Average Number of Shares Outstanding, Basic Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] After first anniversary through second anniversary of closing date Debt Instrument, Redemption, Period Two [Member] Revenues: Revenues [Abstract] Total cost of goods sold Cost of Revenue Michael Raab [Member] Michael Raab Comprehensive loss: Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract] Proceeds from issuance of common stock under equity incentive and stock purchase plans Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Statement [Line Items] Statement [Line Items] Concentration Risk [Table] Concentration Risk [Table] Options vested and expected to vest (shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Laboratory equipment Laboratory Equipment [Member] Laboratory Equipment [Member] Maximum aggregate offering price Maximum Aggregate Offering Price Amount of maximum aggregate offering price. Tax Credit Carryforward [Axis] Tax Credit Carryforward [Axis]